ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
March 30, 2023 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices
March 21, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
March 16, 2023 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA),...
ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference
March 10, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus to Present at Two Upcoming Investor Conferences in March 2023
March 01, 2023 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Appoints Brian Dow as Chief Financial Officer
March 01, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance
February 01, 2023 17:15 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference
January 26, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)
December 21, 2022 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
First prospective crossover study comparing the effectiveness of precision oral appliance therapy as front-line therapy relative to CPAP for the treatment of obstructive sleep apnea ProSomnus...
ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea
December 19, 2022 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...